Can a common antiviral save lives in advanced HIV?
NCT ID NCT07379203
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether valganciclovir, a drug that stops CMV from multiplying, can safely lower CMV levels in the blood of people with advanced HIV. About 130 adults and adolescents with very weak immune systems will be randomly assigned to take either valganciclovir or a placebo daily for 4 weeks, while continuing standard HIV care. Researchers will monitor side effects and check if the drug reduces hospitalizations or deaths.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Valganciclovir
- What this could lead to
- If it works, this could point toward a standard treatment to reduce CMV-related deaths in people with advanced HIV.
- What could go wrong
- This is a phase 2b trial with only 130 participants, so results may not apply broadly. Valganciclovir can cause serious side effects like low blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HIV DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an antibody boost help transplant patients beat CMV faster?
- Can a community health worker program save lives in advanced HIV?
- Zambia launches massive study to uncover why some HIV patients still get very sick
- Washing kidneys to stop hidden virus: new trial aims to make transplants safer
- Study aims to keep advanced HIV patients connected to care after leaving hospital
- Could a common antiviral protect babies from CMV in the womb?